|
BCG infection
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MDSCs that were generated from murine bone marrow (MDSCs) of wild-type (WT) or <i>Cav1</i><sup>-/-</sup> mice upregulated Cav-1, TLR4 and TLR2 expression after BCG infection on the cell surface.
|
31849990 |
2019 |
|
Endometritis
|
0.060 |
Biomarker
|
disease |
BEFREE |
Selenium alleviates lipopolysaccharide-induced endometritis via regulating the recruitment of TLR4 into lipid rafts in mice.
|
31845693 |
2020 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
This study aimed to assess whether genetic variants of dendritic cell-associated C-type lectine-1 (Dectin-1), Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4), and myeloid differentiation primary response 88 (MyD88) influence the susceptibility to pulmonary invasive fungal disease (IFD) in patients with acute myeloid leukemia (AML) from a Chinese Han population.
|
31845221 |
2019 |
|
Invasive Fungal Infections
|
0.010 |
GeneticVariation
|
group |
BEFREE |
This study aimed to assess whether genetic variants of dendritic cell-associated C-type lectine-1 (Dectin-1), Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4), and myeloid differentiation primary response 88 (MyD88) influence the susceptibility to pulmonary invasive fungal disease (IFD) in patients with acute myeloid leukemia (AML) from a Chinese Han population.
|
31845221 |
2019 |
|
Intrinsic Factor Deficiency
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There were no significant associations between pulmonary IFD and the remaining Dectin-1 SNPs (rs16910526), TLR2 (rs5743708), TLR4 (rs4986790 and rs4986791) or MyD88 (rs4988453 and rs4988457).
|
31845221 |
2019 |
|
Memory impairment
|
0.140 |
Biomarker
|
phenotype |
BEFREE |
Geniposidic acid ameliorates spatial learning and memory deficits and alleviates neuroinflammation via inhibiting HMGB-1 and downregulating TLR4/2 signaling pathway in APP/PS1 mice.
|
31837991 |
2020 |
|
Schizophrenia
|
0.380 |
Biomarker
|
disease |
BEFREE |
This finding suggests possible contribution of TLR4 in immunopathogenetic pathway of schizophrenia.
|
31837816 |
2020 |
|
Periodontitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS Taken together, our results revealed that SAC effectively attenuates LPS-induced inflammation and apoptosis via the TLR4/NF-kappaB pathway and that SAC is effective in treating periodontitis.
|
31831723 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of HMGB1 could be negatively regulated by HSF1, and the TLR4/MyD88/NF-κB signal pathway was involved in HSF1/HMGB1-mediated regulation of asthma.
|
31825792 |
2020 |
|
Overweight or obesity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
A Carbohydrate Beverage Reduces Monocytes Expressing TLR4 in Children with Overweight or Obesity.
|
31825075 |
2020 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of note, network analysis comparing TB-associated host genes identified in the current HIV-negative TB cohort to TB-associated genes identified in our previously published Ethiopian HIV-positive TB cohort, revealed an over-representation of pattern recognition receptors including TLR2 and TLR4 in the HIV-positive cohort which was not seen in the HIV-negative cohort.
|
31821366 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.080 |
Biomarker
|
disease |
BEFREE |
It consists of naked mRNA based on cytotoxic T lymphocyte (CTL) targets of subdominant and conserved HIV-1 regions (HTI), in combination with mRNAs encoding constitutively active TLR4, the ligand for CD40 and CD70 as adjuvants (TriMix).
|
31817794 |
2019 |
|
Cystic Fibrosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
In subjects with CF we found that lower TLR4-agonist-induced IL-8 was associated with lower FEV<sub>1</sub>% at enrollment (p<0.001) and with greater five year FEV<sub>1</sub>% decline (p<0.001).
|
31813753 |
2019 |
|
Dermatitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Skin application of the ligand ameliorated a TLR4 ligand-induced dermatitis in mice.
|
31811054 |
2019 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with TLR4 inhibitor resulted in lower liver inflammation in mice with NASH.
|
31808577 |
2019 |
|
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with TLR4 inhibitor resulted in lower liver inflammation in mice with NASH.
|
31808577 |
2019 |
|
Lupus Nephritis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Co-Delivery Of Dihydroartemisinin And HMGB1 siRNA By TAT-Modified Cationic Liposomes Through The TLR4 Signaling Pathway For Treatment Of Lupus Nephritis.
|
31806961 |
2019 |
|
Subarachnoid Hemorrhage
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, curcumin treatment also decreased the expressions of TLR4, Myd88 and NF-κB at 24 h post SAH.
|
31803007 |
2019 |
|
Subarachnoid Hemorrhage
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The results indicated that Exo from bone marrow mesenchymal stem cells could alleviate EBI following SAH through miRNA129-5p's anti-inflammation and anti-apoptosis effects via quenching the activity of HMGB1-TLR4 pathway.
|
31801411 |
2020 |
|
Malignant tumor of cervix
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Author Correction: Association of TLR4 and TLR9 polymorphisms and haplotypes with cervical cancer susceptibility.
|
31796857 |
2019 |
|
Cervix carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Author Correction: Association of TLR4 and TLR9 polymorphisms and haplotypes with cervical cancer susceptibility.
|
31796857 |
2019 |
|
cervical cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Author Correction: Association of TLR4 and TLR9 polymorphisms and haplotypes with cervical cancer susceptibility.
|
31796857 |
2019 |
|
Skin callus
|
0.010 |
Biomarker
|
disease |
BEFREE |
TLR4 knockout promoted fracture healing, reduced the number of osteoclasts, increased bone callus volume (BV) and callus mineralized volume fraction (BV/TV%) (P < 0.05), increased the maximum torque and torsional stiffness of callus (P < 0.05), reduced TNF-α, IL-1β and IL-6 expression (P < 0.01), and increased the expression levels of β-catenin, Wnt4, Wnt5B, PCNA and BMP-2 (P < 0.01).
|
31796334 |
2020 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Activation of TLR4 modulates vascular smooth muscle cells (VSMCs) phenotype and contributes to cardiovascular changes after sepsis.
|
31794773 |
2020 |
|
Septicemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Activation of TLR4 modulates vascular smooth muscle cells (VSMCs) phenotype and contributes to cardiovascular changes after sepsis.
|
31794773 |
2020 |